BSBruna Ferri Serafini

Bruna Ferri Serafini

*This is an algorithmically generated author record based on publicly available information.

Bruna Ferri Serafini has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiolipin-Based Electrochemical Biosensor for Non-treponemal Antibody Detection Using Screen-Printed Electrodes: A Proof-of-Concept Study

    by Duane da Silva Moraes, Bruna Ferri Serafini, Felipe Longaray Kadel, Gabriela VictórIa de Mello Jantzch, Milleny Germann Souza, Willyan Hasenkamp Carreira, Antonio Shigueaki Takimi, Julia Konzen Moreira

    Syphilis remains a major public health concern. Although non-treponemal tests are widely used for screening and treatment monitoring, their interpretation relies on visual assessment of flocculation. Here, an amperometric biosensor using isolated cardiolipin (0.03–0.12%) as the sole biorecognition element was developed on carbon/graphene screen-printed electrodes. The 0.06% concentration was selected for subsequent experiments, and the biosensor discriminated positive and negative control materials across two electrode batches. Progressive positive-control dilution produced a systematic electrochemical response (R2 = 0.921). Electrode functionalization significantly affected the response (p < 0.001), supporting the contribution of immobilized cardiolipin. Discrimination was maintained under physiological and pathological glucose conditions (adjusted p < 0.001). These findings provide a preliminary proof-of-concept for cardiolipin-based electrochemical assessment of non-treponemal antibody reactivity. Further studies using clinical samples are required to establish analytical and clinical performance and investigate semiquantitative evaluation by correlating electrochemical responses with defined serological titers.

  • Open Access

    From laboratory to point of care: Clinical performance and validation of bSens.INR for prothrombin time and INR monitoring

    by Julia Konzen Moreira, Gabriela Victória de Mello Jantzch, Duane da Silva Moraes, Bruna Ferri Serafini, Milleny Germann Souza, Marcele Arais Hocevar, Rodrigo Ritzel Bernasconi, Fernanda Santos dos Santos, Willyan Hasenkamp Carreira

  • Open Access

    Analytical and Clinical Validation of a Remote Laboratory Test for Prothrombin Time and INR Determination in Patients with Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus

    by Gabriela Victória de Mello Jantzch, Rodrigo Ritzel Bernasconi, Milleny Germann Souza, Duane da Silva Moraes, Bruna Ferri Serafini, Leonardo Peterson dos Santos, Julia Konzen Moreira, Ricardo Machado Xavier

    Antiphospholipid syndrome (APS) is an autoimmune disorder associated with antiphospholipid antibodies, leading to coagulation imbalance, thrombosis, and obstetric complications. It may occur as a primary condition or in association with systemic lupus erythematosus (SLE). Patients with APS often require long-term anticoagulation therapy, monitored by prothrombin time (PT) expressed as international normalized ratio (INR). Remote laboratory testing (RLT) devices may improve monitoring by providing faster and more convenient results; however, their accuracy in APS patients remains uncertain. This study aimed to validate a rapid and portable device (bSens.INR) for PT/INR measurement in patients with APS and SLE receiving warfarin, compared to a control group without these conditions. Accuracy, repeatability, and agreement with the standard laboratory method were evaluated according to established guidelines. A total of 40 PT/INR measurements were obtained using the bSens.INR and 20 using the standard method. Overall concordance was 77.5%, with lower agreement in APS/SLE patients (60%) compared to controls (95%). Approved results showed 100% repeatability. A strong positive correlation was observed between methods (Spearman r = 0.80, p < 0.0001), while Bland–Altman analysis indicated a bias of 0.26 INR units. The presence of antiphospholipid antibodies appears to interfere with PT/INR measurements obtained by the bSens.INR, reducing accuracy in APS and SLE patients. Although the device shows promising performance, its use in autoimmune populations should be approached with caution, reinforcing previous findings on the limitations of RLT in these conditions.